Future development of small molecule aCDase activators or ASM inhibitors, combined with testing in preclinical models of hepatitis or respiratory viruses, could pave the way for clinically viable strategies that preserve host defense while limiting immune-mediated tissue damage. This evidence concerns the gene ASAH1 and hepatitis A virus infection.